clinical trial · NCT05253833
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
GoutArthritis, GoutyHyperuricemiaGout ChronicAR882 Dose 1AR882 Dose 2Allopurinol Tablet
brief summary
This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.
started
Aug 12, 2022
primary completion
Aug 13, 2024
completion
Oct 28, 2024
last updated
Jan 29, 2025
official title
A Phase 2, Randomized, Open-Label, Allopurinol-Controlled, Multicenter Study With Two Optional Extensions to Evaluate the Safety and Efficacy of AR882 Alone or in Combination With Allopurinol in Tophaceous Gout Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol